{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:33:24Z","timestamp":1792640004312,"version":"4.5.0"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T00:00:00Z","timestamp":1697846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T00:00:00Z","timestamp":1697846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s12072-023-10599-6","type":"journal-article","created":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T08:02:27Z","timestamp":1697875347000},"page":"4-31","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1025-8895","authenticated-orcid":false,"given":"Ming","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Hua","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Ping","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Shan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Jun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Liang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Jin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Feng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang-Shun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Hui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Peng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Wen","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Lan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Long","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Ming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Zhi","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong-Guo","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Hai","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Hui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Feng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang-Kui","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Zhang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Zhe","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,21]]},"reference":[{"issue":"3","key":"10599_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"10204","key":"10599_CR2","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S0140-6736(19)30427-1","volume":"394","author":"M Zhou","year":"2019","unstructured":"Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019;394(10204):1145\u20131158","journal-title":"Lancet"},{"issue":"4","key":"10599_CR3","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378\u2013390","journal-title":"N Engl J Med"},{"issue":"1","key":"10599_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25\u201334","journal-title":"Lancet Oncol"},{"issue":"10126","key":"10599_CR5","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163\u20131173","journal-title":"Lancet"},{"issue":"20","key":"10599_CR6","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u20131905","journal-title":"N Engl J Med"},{"issue":"8","key":"10599_CR7","doi-asserted-by":"publisher","first-page":"2100070","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1(8):2100070","journal-title":"NEJM Evid"},{"issue":"1","key":"10599_CR8","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3892\/ol.2017.6222","volume":"14","author":"ZH Chen","year":"2017","unstructured":"Chen ZH, Hong YF, Lin J, Li X, Wu DH, Wen JY, et al. Validation and ranking of seven staging systems of hepatocellular carcinoma. Oncol Lett. 2017;14(1):705\u2013714","journal-title":"Oncol Lett"},{"issue":"1","key":"10599_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000346220","volume":"2","author":"P Song","year":"2013","unstructured":"Song P, Gao J, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, et al. Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china. Liver Cancer. 2013;2(1):31\u201339","journal-title":"Liver Cancer"},{"key":"10599_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13542","volume":"2","author":"M Guarino","year":"2021","unstructured":"Guarino M, Cucchetti A, Pontillo G, Farinati F, Benevento F, Rapaccini GL, et al. Pattern of macrovascular invasion in hepatocellular carcinoma. Eur J Clin Invest. 2021;2: e13542","journal-title":"Eur J Clin Invest"},{"key":"10599_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1158\/1538-7445.AM2021-CT009","volume":"81","author":"RS Finn","year":"2021","unstructured":"Finn RS, Qin SK, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC). Cancer Res. 2021;81:13","journal-title":"Cancer Res"},{"issue":"4","key":"10599_CR12","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862\u2013873","journal-title":"J Hepatol"},{"issue":"7","key":"10599_CR13","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study. Lancet Oncol. 2021;22(7):977\u2013990","journal-title":"Lancet Oncol"},{"issue":"7","key":"10599_CR14","doi-asserted-by":"publisher","first-page":"S1402","DOI":"10.1016\/j.annonc.2022.08.033","volume":"33","author":"S Qin","year":"2022","unstructured":"Qin S, Kudo M, Meyer T, Finn RS, Vogel A, Bai Y, et al. Final analysis of RATIONALE-301: randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Ann Oncol. 2022;33(7):S1402\u2013S1403","journal-title":"Ann Oncol"},{"key":"10599_CR15","first-page":"2","volume":"2","author":"S Qin","year":"2023","unstructured":"Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;2:2","journal-title":"Lancet"},{"issue":"3\u20134","key":"10599_CR16","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1159\/000343875","volume":"3","author":"M Kudo","year":"2014","unstructured":"Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, et al. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the liver cancer study group of Japan. Liver cancer. 2014;3(3\u20134):458\u2013468","journal-title":"Liver cancer"},{"issue":"3","key":"10599_CR17","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.annonc.2019.12.001","volume":"31","author":"LT Chen","year":"2020","unstructured":"Chen LT, Martinelli E, Cheng AL, Pentheroudakis G, Qin S, Bhattacharyya GS, et al. Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with intermediate and advanced\/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO MOS and SSO. Ann Oncol. 2020;31(3):334\u2013351","journal-title":"Ann Oncol"},{"key":"10599_CR18","doi-asserted-by":"crossref","unstructured":"2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol 2022;28(4):583\u2013705.","DOI":"10.3350\/cmh.2022.0294"},{"issue":"1","key":"10599_CR19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/BF00402774","volume":"111","author":"R Bartkowski","year":"1986","unstructured":"Bartkowski R, Berger MR, Aguiar JL, Henne TH, Dorsam J, Geelhaar GH, et al. Experiments on the efficacy and toxicity of locoregional chemotherapy of liver tumors with 5-fluoro-2\u2019-deoxyuridine (FUDR) and 5-fluorouracil (5-FU) in an animal model. J Cancer Res Clin Oncol. 1986;111(1):42\u201346","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"10599_CR20","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1159\/000508724","volume":"9","author":"K Ueshima","year":"2020","unstructured":"Ueshima K, Ogasawara S, Ikeda M, Yasui Y, Terashima T, Yamashita T, et al. Hepatic arterial infusion chemotherapy versus sorafenib in patients with advanced hepatocellular carcinoma. Liver cancer. 2020;9(5):583\u2013595","journal-title":"Liver cancer"},{"issue":"3","key":"10599_CR21","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000514174","volume":"10","author":"M Kudo","year":"2021","unstructured":"Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer. 2021;10(3):181\u2013223","journal-title":"Liver Cancer"},{"issue":"3","key":"10599_CR22","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3350\/cmh.2013.19.3.288","volume":"19","author":"MJ Oh","year":"2013","unstructured":"Oh MJ, Lee HJ, Lee SH. Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy. Clin Mol Hepatol. 2013;19(3):288\u2013299","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"10599_CR23","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00535-014-0978-3","volume":"50","author":"DS Song","year":"2015","unstructured":"Song DS, Song MJ, Bae SH, Chung WJ, Jang JY, Kim YS, et al. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. J Gastroenterol. 2015;50(4):445\u2013454","journal-title":"J Gastroenterol"},{"issue":"3","key":"10599_CR24","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00280-018-3638-0","volume":"82","author":"JH Choi","year":"2018","unstructured":"Choi JH, Chung WJ, Bae SH, Song DS, Song MJ, Kim YS, et al. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer Chemother Pharmacol. 2018;82(3):469\u2013478","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10599_CR25","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jfma.2017.09.007","volume":"117","author":"Management consensus guideline for hepatocellular carcinoma","year":"2018","unstructured":"Management consensus guideline for hepatocellular carcinoma. 2016 updated by the Taiwan liver cancer association and the gastroenterological society of Taiwan. J Formos Med Assoc. 2018;117(5):381\u2013403","journal-title":"J Formos Med Assoc"},{"issue":"4","key":"10599_CR26","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1159\/000367737","volume":"4","author":"CC Lin","year":"2015","unstructured":"Lin CC, Hung CF, Chen WT, Lin SM. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein thrombosis: impact of early response to 4 weeks of treatment. Liver cancer. 2015;4(4):228\u2013240","journal-title":"Liver cancer"},{"key":"10599_CR27","unstructured":"Chinese Society of Clinical Oncology (CSCO). Guidelines for Hepatocellular Carcinoma (version 2020). Beijing, China: People\u2019s Medical Publishing House CoLtd (PMPH), 2020."},{"issue":"1","key":"10599_CR28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jhep.2018.02.008","volume":"69","author":"N Lyu","year":"2018","unstructured":"Lyu N, Kong Y, Mu L, Lin Y, Li J, Liu Y, et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil\/leucovorin vs sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2018;69(1):60\u201369","journal-title":"J Hepatol"},{"issue":"7","key":"10599_CR29","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","volume":"5","author":"M He","year":"2019","unstructured":"He M, Li Q, Zou R, Shen J, Fang W, Tan G, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol. 2019;5(7):953\u2013960","journal-title":"JAMA Oncol"},{"issue":"2","key":"10599_CR30","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1148\/radiol.211545","volume":"303","author":"K Zheng","year":"2022","unstructured":"Zheng K, Zhu X, Fu S, Cao G, Li WQ, Xu L, et al. Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib for hepatocellular carcinoma with major portal vein tumor thrombosis: a randomized trial. Radiology. 2022;303(2):455\u2013464","journal-title":"Radiology"},{"issue":"2","key":"10599_CR31","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1200\/JCO.21.00608","volume":"40","author":"QJ Li","year":"2022","unstructured":"Li QJ, He MK, Chen HW, Fang WQ, Zhou YM, Xu L, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial. J Clin Oncol. 2022;40(2):150\u2013160","journal-title":"J Clin Oncol"},{"issue":"5","key":"10599_CR32","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1200\/JCO.21.01963","volume":"40","author":"N Lyu","year":"2022","unstructured":"Lyu N, Wang X, Li JB, Lai JF, Chen QF, Li SL, et al. Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1). J Clin Oncol. 2022;40(5):468\u2013480","journal-title":"J Clin Oncol"},{"key":"10599_CR33","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejca.2022.07.005","volume":"174","author":"Z Lai","year":"2022","unstructured":"Lai Z, He M, Bu X, Xu Y, Huang Y, Wen D, et al. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: a biomolecular exploratory, phase II trial. Eur J Cancer. 2022;174:68\u201377","journal-title":"Eur J Cancer"},{"issue":"16","key":"10599_CR34","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1200\/JCO.2022.40.16_suppl.4106","volume":"40","author":"Y-K Gu","year":"2022","unstructured":"Gu Y-K, Zhang T-Q, Zuo M-X, Geng Z-J, Li J-B, Huang Z-L, et al. Hepatic artery infusion chemotherapy (HAIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in BCLC stage c: a prospective, single-arm, phase II trial (TRIPLET study). J Clin Oncol. 2022;40(16):4106","journal-title":"J Clin Oncol"},{"issue":"5","key":"10599_CR35","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1159\/000524893","volume":"11","author":"K Ueshima","year":"2022","unstructured":"Ueshima K, Komemushi A, Aramaki T, Iwamoto H, Obi S, Sato Y, et al. Clinical practice guidelines for hepatic arterial infusion chemotherapy with a port system proposed by the Japanese society of interventional radiology and Japanese society of implantable port assisted treatment. Liver cancer. 2022;11(5):407\u2013425","journal-title":"Liver cancer"},{"issue":"2","key":"10599_CR36","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1136\/gutjnl-2017-314138","volume":"67","author":"N Lyu","year":"2018","unstructured":"Lyu N, Lin Y, Kong Y, Zhang Z, Liu L, Zheng L, et al. FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil\/leucovorin for advanced hepatocellular carcinoma. Gut. 2018;67(2):395\u2013396","journal-title":"Gut"},{"issue":"1","key":"10599_CR37","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s40880-017-0251-2","volume":"36","author":"MK He","year":"2017","unstructured":"He MK, Le Y, Li QJ, Yu ZS, Li SH, Wei W, et al. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study. Chin J Cancer. 2017;36(1):83","journal-title":"Chin J Cancer"},{"issue":"1","key":"10599_CR38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000449343","volume":"6","author":"M Kudo","year":"2016","unstructured":"Kudo M, Trevisani F, Abou-Alfa GK, Rimassa L. Hepatocellular carcinoma: therapeutic guidelines and medical treatment. Liver cancer. 2016;6(1):16\u201326","journal-title":"Liver cancer"},{"issue":"2","key":"10599_CR39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/jjco\/hyx180","volume":"48","author":"M Ikeda","year":"2018","unstructured":"Ikeda M, Morizane C, Ueno M, Okusaka T, Ishii H, Furuse J. Chemotherapy for hepatocellular carcinoma: current status and future perspectives. Jpn J Clin Oncol. 2018;48(2):103\u2013114","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"10599_CR40","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1159\/000342402","volume":"1","author":"M Kudo","year":"2012","unstructured":"Kudo M. Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. Liver Cancer. 2012;1(2):62\u201370","journal-title":"Liver Cancer"},{"issue":"3","key":"10599_CR41","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1159\/000367746","volume":"4","author":"S Obi","year":"2015","unstructured":"Obi S, Sato S, Kawai T. Current status of hepatic arterial infusion chemotherapy. Liver cancer. 2015;4(3):188\u2013199","journal-title":"Liver cancer"},{"issue":"5","key":"10599_CR42","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1097\/SLA.0000000000000261","volume":"259","author":"D Magge","year":"2014","unstructured":"Magge D, Choudry HA, Zeh HJ 3rd, Cunningham DE, Steel J, Holtzman MP, et al. Outcome analysis of a decade-long experience of isolated hepatic perfusion for unresectable liver metastases at a single institution. Ann Surg. 2014;259(5):953\u2013959","journal-title":"Ann Surg"},{"issue":"6","key":"10599_CR43","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1245\/s10434-014-4272-7","volume":"22","author":"MA Allard","year":"2015","unstructured":"Allard MA, Sebagh M, Baillie G, Lemoine A, Dartigues P, Faitot F, et al. Comparison of complete pathologic response and hepatic injuries between hepatic arterial infusion and systemic administration of oxaliplatin in patients with colorectal liver metastases. Ann Surg Oncol. 2015;22(6):1925\u20131932","journal-title":"Ann Surg Oncol"},{"issue":"17","key":"10599_CR44","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1200\/JCO.2016.71.8346","volume":"35","author":"B Groot Koerkamp","year":"2017","unstructured":"Groot Koerkamp B, Sadot E, Kemeny NE, Gonen M, Leal JN, Allen PJ, et al. Perioperative hepatic arterial infusion pump chemotherapy is associated with longer survival after resection of colorectal liver metastases: a propensity score analysis. J Clin Oncol. 2017;35(17):1938\u20131944","journal-title":"J Clin Oncol"},{"issue":"28","key":"10599_CR45","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1200\/JCO.2012.44.5643","volume":"31","author":"S Qin","year":"2013","unstructured":"Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil\/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2013;31(28):3501\u20133508","journal-title":"J Clin Oncol"},{"issue":"1","key":"10599_CR46","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1186\/s12885-019-6198-8","volume":"19","author":"M Kondo","year":"2019","unstructured":"Kondo M, Morimoto M, Kobayashi S, Ohkawa S, Hidaka H, Nakazawa T, et al. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial. BMC Cancer. 2019;19(1):954","journal-title":"BMC Cancer"},{"issue":"6","key":"10599_CR47","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S2468-1253(18)30078-5","volume":"3","author":"M Kudo","year":"2018","unstructured":"Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, et al. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. Lancet Gastroenterol Hepatol. 2018;3(6):424\u2013432","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10599_CR48","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1742-1241.2000.tb11930.x","volume":"54","author":"J Cassidy","year":"2000","unstructured":"Cassidy J. Review of oxaliplatin: an active platinum agent in colorectal cancer. Int J Clin Pract. 2000;54(6):399\u2013402","journal-title":"Int J Clin Pract"},{"issue":"4","key":"10599_CR49","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nm.4291","volume":"23","author":"PM Bruno","year":"2017","unstructured":"Bruno PM, Liu Y, Park GY, Murai J, Koch CE, Eisen TJ, et al. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat Med. 2017;23(4):461\u2013471","journal-title":"Nat Med"},{"issue":"11","key":"10599_CR50","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.bcp.2009.07.006","volume":"78","author":"D Theile","year":"2009","unstructured":"Theile D, Grebhardt S, Haefeli WE, Weiss J. Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy. Biochem Pharmacol. 2009;78(11):1366\u20131373","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10599_CR51","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41568-020-00308-y","volume":"21","author":"S Rottenberg","year":"2021","unstructured":"Rottenberg S, Disler C, Perego P. The rediscovery of platinum-based cancer therapy. Nat Rev Cancer. 2021;21(1):37\u201350","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10599_CR52","doi-asserted-by":"publisher","first-page":"895","DOI":"10.2165\/00003495-200060040-00005","volume":"60","author":"CR Culy","year":"2000","unstructured":"Culy CR, Clemett D, Wiseman LR. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs. 2000;60(4):895\u2013924","journal-title":"Drugs"},{"issue":"10","key":"10599_CR53","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1023\/A:1008213732429","volume":"9","author":"E Raymond","year":"1998","unstructured":"Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998;9(10):1053\u20131071","journal-title":"Ann Oncol"},{"issue":"13","key":"10599_CR54","first-page":"3500","volume":"54","author":"EL Mamenta","year":"1994","unstructured":"Mamenta EL, Poma EE, Kaufmann WK, Delmastro DA, Grady HL, Chaney SG. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res. 1994;54(13):3500\u20133505","journal-title":"Cancer Res"},{"issue":"1","key":"10599_CR55","doi-asserted-by":"publisher","first-page":"2093518","DOI":"10.1080\/2162402X.2022.2093518","volume":"11","author":"P Liu","year":"2022","unstructured":"Liu P, Chen J, Zhao L, Hollebecque A, Kepp O, Zitvogel L, et al. PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer. Oncoimmunology. 2022;11(1):2093518","journal-title":"Oncoimmunology"},{"issue":"4","key":"10599_CR56","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1008866","volume":"4","author":"J Pol","year":"2015","unstructured":"Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I, et al. Trial watch: immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology. 2015;4(4): e1008866","journal-title":"Oncoimmunology"},{"issue":"6","key":"10599_CR57","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1097\/01.cad.0000131684.06390.fe","volume":"15","author":"R Dzodic","year":"2004","unstructured":"Dzodic R, Gomez-Abuin G, Rougier P, Bonnay M, Ardouin P, Gouyette A, et al. Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: comparative results with cisplatin using a rabbit VX2 tumor model. Anticancer Drugs. 2004;15(6):647\u2013650","journal-title":"Anticancer Drugs"},{"issue":"1","key":"10599_CR58","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jhep.2014.03.012","volume":"61","author":"L Yin","year":"2014","unstructured":"Yin L, Li H, Li AJ, Lau WY, Pan ZY, Lai EC, et al. Partial hepatectomy vs transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT. J Hepatol. 2014;61(1):82\u201388","journal-title":"J Hepatol"},{"issue":"4","key":"10599_CR59","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s12032-013-0696-3","volume":"30","author":"SH Li","year":"2013","unstructured":"Li SH, Wei W, Guo RP, Shi M, Guo ZX, Chen ZY, et al. Long-term outcomes after curative resection for patients with macroscopically solitary hepatocellular carcinoma without macrovascular invasion and an analysis of prognostic factors. Med Oncol. 2013;30(4):696","journal-title":"Med Oncol"},{"issue":"3","key":"10599_CR60","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1245\/s10434-021-10903-4","volume":"29","author":"Y Pan","year":"2022","unstructured":"Pan Y, Mei J, Chen J, Zhang D, Wang J, Wang X, et al. Comparison between portal vein perfusion chemotherapy and neoadjuvant hepatic arterial infusion chemotherapy for resectable intermediate to advanced stage hepatocellular carcinoma. Ann Surg Oncol. 2022;29(3):2016\u20132029","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"10599_CR61","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1245\/s10434-020-08601-8","volume":"27","author":"S Li","year":"2020","unstructured":"Li S, Mei J, Wang Q, Guo Z, Lu L, Ling Y, et al. Postoperative adjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of hepatocellular carcinoma patients with microvascular invasion: a preliminary report of a phase iii, randomized controlled clinical trial. Ann Surg Oncol. 2020;27(13):5183\u20135190","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10599_CR62","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.hpb.2018.11.012","volume":"21","author":"E Bl\u00fcthner","year":"2019","unstructured":"Bl\u00fcthner E, Jara M, Shrestha R, Faber W, Pratschke J, Stockmann M, et al. The predictive value of future liver remnant function after liver resection for HCC in noncirrhotic and cirrhotic patients. HPB (Oxford). 2019;21(7):912\u2013922","journal-title":"HPB (Oxford)"},{"key":"10599_CR63","first-page":"15","volume":"39","author":"SH Li","year":"2021","unstructured":"Li SH, Zhong C, Li Q, Zou JW, Wang QX, Shang CZ, et al. Neoadjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A\/B hepatocellular carcinoma patients beyond Milan criteria: an interim analysis of a multi-center, phase 3, randomized, controlled clinical trial. J Clin Oncol. 2021;39:15","journal-title":"J Clin Oncol"},{"issue":"10","key":"10599_CR64","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S1470-2045(02)00873-2","volume":"3","author":"JD Schwartz","year":"2002","unstructured":"Schwartz JD, Schwartz M, Mandeli J, Sung M. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol. 2002;3(10):593\u2013603","journal-title":"Lancet Oncol"},{"issue":"2","key":"10599_CR65","first-page":"124","volume":"8","author":"WY Lau","year":"2009","unstructured":"Lau WY, Lai EC, Lau SH. The current role of neoadjuvant\/adjuvant\/chemoprevention therapy in partial hepatectomy for hepatocellular carcinoma: a systematic review. Hepatobiliary Pancreat Dis Int. 2009;8(2):124\u2013133","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"4","key":"10599_CR66","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1245\/s10434-015-5008-z","volume":"23","author":"JJ Sun","year":"2016","unstructured":"Sun JJ, Wang K, Zhang CZ, Guo WX, Shi J, Cong WM, et al. Postoperative adjuvant transcatheter arterial chemoembolization after R0 hepatectomy improves outcomes of patients who have hepatocellular carcinoma with microvascular invasion. Ann Surg Oncol. 2016;23(4):1344\u20131351","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10599_CR67","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1200\/JCO.22.01142","volume":"41","author":"SH Li","year":"2023","unstructured":"Li SH, Mei J, Cheng Y, Li Q, Wang QX, Fang CK, et al. Postoperative adjuvant hepatic arterial infusion chemotherapy with FOLFOX in hepatocellular carcinoma with microvascular invasion: a multicenter, phase III Randomized Study. J Clin Oncol. 2023;41(10):1898\u20131908","journal-title":"J Clin Oncol"},{"issue":"5","key":"10599_CR68","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","volume":"35","author":"CM Lo","year":"2002","unstructured":"Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164\u20131171","journal-title":"Hepatology"},{"issue":"8","key":"10599_CR69","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.jvir.2018.03.027","volume":"29","author":"MK He","year":"2018","unstructured":"He MK, Zou RH, Wei W, Shen JX, Zhao M, Zhang YF, et al. Comparison of stable and unstable ethiodized oil emulsions for transarterial chemoembolization of hepatocellular carcinoma: results of a single-center double-blind prospective randomized controlled trial. J Vasc Interv Radiol. 2018;29(8):1068\u201377.e2","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"10599_CR70","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1365-2036.2006.02704.x","volume":"23","author":"YH Huang","year":"2006","unstructured":"Huang YH, Wu JC, Chen SC, Chen CH, Chiang JH, Huo TI, et al. Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter. Aliment Pharmacol Ther. 2006;23(1):129\u2013135","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10599_CR71","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1007\/s11605-022-05421-x","volume":"26","author":"S Chen","year":"2022","unstructured":"Chen S, Yuan B, Yu W, Wang X, He C, Chen C. Comparison of arterial infusion chemotherapy and chemoembolization for locally advanced hepatocellular carcinoma: a multicenter retrospective study. J Gastrointest Surg. 2022;26(11):2292\u20132300","journal-title":"J Gastrointest Surg"},{"issue":"4","key":"10599_CR72","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.jhep.2019.11.016","volume":"72","author":"A Cucchetti","year":"2020","unstructured":"Cucchetti A, Zhong J, Berhane S, Toyoda H, Shi K, Tada T, et al. The chances of hepatic resection curing hepatocellular carcinoma. J Hepatol. 2020;72(4):711\u2013717","journal-title":"J Hepatol"},{"issue":"1","key":"10599_CR73","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s40273-013-0109-7","volume":"32","author":"FT Shaya","year":"2014","unstructured":"Shaya FT, Breunig IM, Seal B, Mullins CD, Chirikov VV, Hanna N. Comparative and cost effectiveness of treatment modalities for hepatocellular carcinoma in SEER-Medicare. Pharmacoeconomics. 2014;32(1):63\u201374","journal-title":"Pharmacoeconomics"},{"key":"10599_CR74","doi-asserted-by":"publisher","first-page":"999","DOI":"10.2147\/JHC.S379326","volume":"9","author":"J Wang","year":"2022","unstructured":"Wang J, Zheng Z, Wu T, Li W, Wang J, Pan Y, et al. Hepatic arterial infusion chemotherapy as a timing strategy for conversion surgery to treat hepatocellular carcinoma: a single-center real-world study. J Hepatocell Carcinoma. 2022;9:999\u20131010","journal-title":"J Hepatocell Carcinoma"},{"key":"10599_CR75","first-page":"6670367","volume":"2021","author":"BJ Liu","year":"2021","unstructured":"Liu BJ, Gao S, Zhu X, Guo JH, Kou FX, Liu SX, et al. Combination therapy of chemoembolization and hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis compared with chemoembolization alone: a propensity score-matched analysis. Biomed Res Int. 2021;2021:6670367","journal-title":"Biomed Res Int"},{"key":"10599_CR76","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.2147\/JHC.S339379","volume":"8","author":"J Huang","year":"2021","unstructured":"Huang J, Huang W, Zhan M, Guo Y, Liang L, Cai M, et al. Drug-eluting bead transarterial chemoembolization combined with FOLFOX-based hepatic arterial infusion chemotherapy for large or huge hepatocellular carcinoma. J Hepatocell Carcinoma. 2021;8:1445\u20131458","journal-title":"J Hepatocell Carcinoma"},{"issue":"3","key":"10599_CR77","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/jso.20301","volume":"91","author":"FA Scappaticci","year":"2005","unstructured":"Scappaticci FA, Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol. 2005;91(3):173\u2013180","journal-title":"J Surg Oncol"},{"issue":"21","key":"10599_CR78","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1200\/JCO.2007.15.4138","volume":"26","author":"HS Hochster","year":"2008","unstructured":"Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study. J Clin Oncol. 2008;26(21):3523\u20133529","journal-title":"J Clin Oncol"},{"issue":"3","key":"10599_CR79","doi-asserted-by":"publisher","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","volume":"19","author":"AB Benson","year":"2021","unstructured":"Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(3):329\u2013359","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"10599_CR80","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jhep.2012.06.014","volume":"57","author":"J Bruix","year":"2012","unstructured":"Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57(4):821\u2013829","journal-title":"J Hepatol"},{"issue":"1","key":"10599_CR81","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/hep.27443","volume":"61","author":"EG Giannini","year":"2015","unstructured":"Giannini EG, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, et al. Prognosis of untreated hepatocellular carcinoma. Hepatology. 2015;61(1):184\u2013190","journal-title":"Hepatology"},{"issue":"2","key":"10599_CR82","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1016\/S1470-2045(16)30569-1","volume":"18","author":"A Granito","year":"2017","unstructured":"Granito A, Bolondi L. Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis. Lancet Oncol. 2017;18(2):e101\u2013e112","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"10599_CR83","doi-asserted-by":"publisher","first-page":"S157","DOI":"10.1016\/j.acra.2021.01.024","volume":"28","author":"SJ Hsu","year":"2021","unstructured":"Hsu SJ, Xu X, Chen MP, Zhao ZY, Wang Y, Yin X, et al. Hepatic arterial infusion chemotherapy with modified FOLFOX as an alternative treatment option in advanced hepatocellular carcinoma patients with failed or unsuitability for transarterial chemoembolization. Acad Radiol. 2021;28(Suppl 1):S157\u2013S166","journal-title":"Acad Radiol"},{"issue":"5","key":"10599_CR84","doi-asserted-by":"publisher","first-page":"631","DOI":"10.21037\/hbsn.2020.03.14","volume":"10","author":"S Li","year":"2021","unstructured":"Li S, Mei J, Wang Q, Shi F, Liu H, Zhao M, et al. Transarterial infusion chemotherapy with FOLFOX for advanced hepatocellular carcinoma: a multi-center propensity score matched analysis of real-world practice. Hepatobiliary Surg Nutr. 2021;10(5):631\u2013645","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"3","key":"10599_CR85","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jvir.2018.09.004","volume":"30","author":"N Lyu","year":"2019","unstructured":"Lyu N, Kong Y, Pan T, Mu L, Li S, Liu Y, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin in hepatocellular cancer with extrahepatic spread. J Vasc Interv Radiol. 2019;30(3):349\u201357.e2","journal-title":"J Vasc Interv Radiol"},{"key":"10599_CR86","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijsu.2015.05.009","volume":"20","author":"ZM Zhang","year":"2015","unstructured":"Zhang ZM, Lai EC, Zhang C, Yu HW, Liu Z, Wan BJ, et al. The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus. Int J Surg. 2015;20:8\u201316","journal-title":"Int J Surg"},{"key":"10599_CR87","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1471-230X-14-84","volume":"14","author":"T Nakazawa","year":"2014","unstructured":"Nakazawa T, Hidaka H, Shibuya A, Okuwaki Y, Tanaka Y, Takada J, et al. Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis. BMC Gastroenterol. 2014;14:84","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"10599_CR88","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","volume":"20","author":"C Yang","year":"2023","unstructured":"Yang C, Zhang H, Zhang L, Zhu AX, Bernards R, Qin W, et al. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2023;20(4):203\u2013222","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10599_CR89","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jhep.2023.03.003","volume":"79","author":"L Rimassa","year":"2023","unstructured":"Rimassa L, Finn RS, Sangro B. Combination immunotherapy for hepatocellular carcinoma. J Hepatol. 2023;79(2):506\u2013515","journal-title":"J Hepatol"},{"issue":"14","key":"10599_CR90","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1002\/cncr.34764","volume":"129","author":"C An","year":"2023","unstructured":"An C, Fu Y, Li W, Zuo M, Wu P. Postprogression treatment of lenvatinib plus PD-1 inhibitor in advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy. Cancer. 2023;129(14):2235\u20132244","journal-title":"Cancer"},{"issue":"11","key":"10599_CR91","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1093\/annonc\/mdw323","volume":"27","author":"M Ikeda","year":"2016","unstructured":"Ikeda M, Shimizu S, Sato T, Morimoto M, Kojima Y, Inaba Y, et al. Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial. Ann Oncol. 2016;27(11):2090\u20132096","journal-title":"Ann Oncol"},{"key":"10599_CR92","first-page":"2","volume":"2","author":"M Ikeda","year":"2023","unstructured":"Ikeda M, Yamashita T, Ogasawara S, Kudo M, Inaba Y, Morimoto M, et al. Multicenter phase II trial of lenvatinib plus hepatic intra-arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma: LEOPARD. Liver Cancer. 2023;2:2","journal-title":"Liver Cancer"},{"issue":"2","key":"10599_CR93","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1148\/radiol.2242011283","volume":"224","author":"AM Covey","year":"2002","unstructured":"Covey AM, Brody LA, Maluccio MA, Getrajdman GI, Brown KT. Variant hepatic arterial anatomy revisited: digital subtraction angiography performed in 600 patients. Radiology. 2002;224(2):542\u2013547","journal-title":"Radiology"},{"key":"10599_CR94","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ejca.2020.03.032","volume":"134","author":"S Chen","year":"2020","unstructured":"Chen S, Zhang K, Liu W, Yu W. Hepatic arterial infusion of oxaliplatin plus raltitrexed in patients with intermediate and advanced stage hepatocellular carcinoma: a phase II, single-arm, prospective study. Eur J Cancer. 2020;134:90\u201398","journal-title":"Eur J Cancer"},{"issue":"8","key":"10599_CR95","first-page":"2203","volume":"47","author":"GD Heggie","year":"1987","unstructured":"Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 1987;47(8):2203\u20132206","journal-title":"Cancer Res"},{"issue":"3","key":"10599_CR96","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2165\/00003495-199855030-00012","volume":"55","author":"NS Gunasekara","year":"1998","unstructured":"Gunasekara NS, Faulds DR. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs. 1998;55(3):423\u2013435","journal-title":"Drugs"},{"issue":"5","key":"10599_CR97","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s00270-017-1874-z","volume":"41","author":"MK He","year":"2018","unstructured":"He MK, Zou RH, Li QJ, Zhou ZG, Shen JX, Zhang YF, et al. Phase II study of sorafenib combined with concurrent hepatic arterial infusion of oxaliplatin, 5-fluorouracil and leucovorin for unresectable hepatocellular carcinoma with major portal vein thrombosis. Cardiovasc Intervent Radiol. 2018;41(5):734\u2013743","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"14","key":"10599_CR98","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1038\/onc.2016.384","volume":"36","author":"SQ Ma","year":"2017","unstructured":"Ma SQ, Cao BR, Zhang H, Luo LP, Ren Y, Hu T, et al. The lack of Raf-1 kinase feedback regulation enhances antiapoptosis in cancer cells. Oncogene. 2017;36(14):2014\u20132022","journal-title":"Oncogene"},{"issue":"2","key":"10599_CR99","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00330-010-1914-4","volume":"21","author":"M Lewin","year":"2011","unstructured":"Lewin M, Fartoux L, Vignaud A, Arriv\u00e9 L, Menu Y, Rosmorduc O. The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study. Eur Radiol. 2011;21(2):281\u2013290","journal-title":"Eur Radiol"},{"key":"10599_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.619461","volume":"11","author":"RB Liang","year":"2021","unstructured":"Liang RB, Zhao Y, He MK, Wen DS, Bu XY, Huang YX, et al. Hepatic arterial infusion chemotherapy of oxaliplatin, fluorouracil, and leucovorin with or without sorafenib as initial treatment for advanced hepatocellular carcinoma. Front Oncol. 2021;11: 619461","journal-title":"Front Oncol"},{"key":"10599_CR101","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2147\/JHC.S298538","volume":"8","author":"J Mei","year":"2021","unstructured":"Mei J, Li SH, Li QJ, Sun XQ, Lu LH, Lin WP, et al. Anti-PD-1 immunotherapy improves the efficacy of hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma. J Hepatocell Carcinoma. 2021;8:167\u2013176","journal-title":"J Hepatocell Carcinoma"},{"key":"10599_CR102","doi-asserted-by":"publisher","first-page":"153303382110638","DOI":"10.1177\/15330338211063848","volume":"20","author":"YJ Xu","year":"2021","unstructured":"Xu YJ, Lai ZC, He MK, Bu XY, Chen HW, Zhou YM, et al. Toripalimab combined with hepatic arterial infusion chemotherapy versus lenvatinib for advanced hepatocellular carcinoma. Technol Cancer Res Treat. 2021;20:15330338211063848","journal-title":"Technol Cancer Res Treat"},{"key":"10599_CR103","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.892192","volume":"12","author":"X Yi","year":"2022","unstructured":"Yi X, Fu Y, Long Q, Zhao Y, Li S, Zhou C, et al. Myosteatosis can predict unfavorable outcomes in advanced hepatocellular carcinoma patients treated with hepatic artery infusion chemotherapy and anti-PD-1 immunotherapy. Front Oncol. 2022;12: 892192","journal-title":"Front Oncol"},{"issue":"2","key":"10599_CR104","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(2):167\u2013192","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10599_CR105","doi-asserted-by":"publisher","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","volume":"20","author":"DS Ettinger","year":"2022","unstructured":"Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(5):497\u2013530","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10599_CR106","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","volume":"22","author":"A Lahiri","year":"2023","unstructured":"Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023;22(1):40","journal-title":"Mol Cancer"},{"issue":"1","key":"10599_CR107","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/sj.bjc.6605465","volume":"102","author":"WM Liu","year":"2010","unstructured":"Liu WM, Fowler DW, Smith P, Dalgleish AG. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer. 2010;102(1):115\u2013123","journal-title":"Br J Cancer"},{"issue":"8","key":"10599_CR108","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1172\/JCI43656","volume":"121","author":"WJ Lesterhuis","year":"2011","unstructured":"Lesterhuis WJ, Punt CJ, Hato SV, Eleveld-Trancikova D, Jansen BJ, Nierkens S, et al. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest. 2011;121(8):3100\u20133108","journal-title":"J Clin Invest"},{"issue":"6","key":"10599_CR109","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s13402-020-00552-2","volume":"43","author":"H Zhu","year":"2020","unstructured":"Zhu H, Shan Y, Ge K, Lu J, Kong W, Jia C. Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy. Cell Oncol (Dordr). 2020;43(6):1203\u20131214","journal-title":"Cell Oncol (Dordr)"},{"issue":"5","key":"10599_CR110","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/ng.3252","volume":"47","author":"K Schulze","year":"2015","unstructured":"Schulze K, Imbeaud S, Letouz\u00e9 E, Alexandrov LB, Calderaro J, Rebouissou S, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015;47(5):505\u2013511","journal-title":"Nat Genet"},{"issue":"1","key":"10599_CR111","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1186\/s12885-021-08858-6","volume":"21","author":"S Chen","year":"2021","unstructured":"Chen S, Xu B, Wu Z, Wang P, Yu W, Liu Z, et al. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study. BMC Cancer. 2021;21(1):1126","journal-title":"BMC Cancer"},{"issue":"26","key":"10599_CR112","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1200\/JCO.20.00808","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38(26):2960\u20132970","journal-title":"J Clin Oncol"},{"issue":"3","key":"10599_CR113","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jhep.2016.10.029","volume":"66","author":"AG Duffy","year":"2017","unstructured":"Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017;66(3):545\u2013551","journal-title":"J Hepatol"},{"key":"10599_CR114","doi-asserted-by":"publisher","first-page":"175883592110027","DOI":"10.1177\/17588359211002720","volume":"13","author":"MK He","year":"2021","unstructured":"He MK, Liang RB, Zhao Y, Xu YJ, Chen HW, Zhou YM, et al. Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma. Ther Adv Med Oncol. 2021;13:17588359211002720","journal-title":"Ther Adv Med Oncol"},{"key":"10599_CR115","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.929141","volume":"13","author":"Y Xin","year":"2022","unstructured":"Xin Y, Cao F, Yang H, Zhang X, Chen Y, Cao X, et al. Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Front Immunol. 2022;13: 929141","journal-title":"Front Immunol"},{"issue":"4","key":"10599_CR116","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","volume":"11","author":"M Omata","year":"2017","unstructured":"Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317\u2013370","journal-title":"Hepatol Int"},{"issue":"4","key":"10599_CR117","doi-asserted-by":"publisher","first-page":"722","DOI":"10.2214\/AJR.17.18219","volume":"209","author":"AS Gomes","year":"2017","unstructured":"Gomes AS, Monteleone PA, Sayre JW, Finn RS, Sadeghi S, Tong MJ, et al. Comparison of triple-drug transcatheter arterial chemoembolization (TACE) with single-drug TACE using doxorubicin-eluting beads: long-term survival in 313 patients. AJR Am J Roentgenol. 2017;209(4):722\u2013732","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"10599_CR118","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1148\/radiol.14131946","volume":"272","author":"K Zhu","year":"2014","unstructured":"Zhu K, Chen J, Lai L, Meng X, Zhou B, Huang W, et al. Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib\u2014a retrospective controlled study. Radiology. 2014;272(1):284\u2013293","journal-title":"Radiology"},{"issue":"2","key":"10599_CR119","doi-asserted-by":"publisher","DOI":"10.1097\/AS9.0000000000000057","volume":"2","author":"B Li","year":"2021","unstructured":"Li B, Qiu J, Zheng Y, Shi Y, Zou R, He W, et al. Conversion to resectability using transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for initially unresectable hepatocellular carcinoma. Ann Surg Open. 2021;2(2): e057","journal-title":"Ann Surg Open"},{"issue":"1","key":"10599_CR120","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/01.RVI.0000052292.26939.59","volume":"14","author":"T Tanaka","year":"2003","unstructured":"Tanaka T, Arai Y, Inaba Y, Matsueda K, Aramaki T, Takeuchi Y, et al. Radiologic placement of side-hole catheter with tip fixation for hepatic arterial infusion chemotherapy. J Vasc Interv Radiol. 2003;14(1):63\u201368","journal-title":"J Vasc Interv Radiol"},{"issue":"3","key":"10599_CR121","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1385\/IJGC:30:3:147","volume":"30","author":"KT Barnett","year":"2001","unstructured":"Barnett KT, Malafa MP. Complications of hepatic artery infusion: a review of 4580 reported cases. Int J Gastrointest Cancer. 2001;30(3):147\u2013160","journal-title":"Int J Gastrointest Cancer"},{"issue":"6","key":"10599_CR122","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/s00535-012-0555-6","volume":"47","author":"T Niizeki","year":"2012","unstructured":"Niizeki T, Sumie S, Torimura T, Kurogi J, Kuromatsu R, Iwamoto H, et al. Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy. J Gastroenterol. 2012;47(6):686\u2013695","journal-title":"J Gastroenterol"},{"issue":"6","key":"10599_CR123","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/hepr.12775","volume":"47","author":"S Tsunematsu","year":"2017","unstructured":"Tsunematsu S, Suda G, Yamasaki K, Kimura M, Takaaki I, Umemura M, et al. Combination of neutrophil-to-lymphocyte ratio and early des-\u03b3-carboxyprothrombin change ratio as a useful predictor of treatment response for hepatic arterial infusion chemotherapy against advanced hepatocellular carcinoma. Hepatol Res. 2017;47(6):533\u2013541","journal-title":"Hepatol Res"},{"issue":"2","key":"10599_CR124","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1440-1746.2011.06867.x","volume":"27","author":"MH Lee","year":"2012","unstructured":"Lee MH, Kim SU, Kim DY, Ahn SH, Choi EH, Lee KH, et al. Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma. J Gastroenterol Hepatol. 2012;27(2):313\u2013322","journal-title":"J Gastroenterol Hepatol"},{"issue":"9","key":"10599_CR125","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/hepr.12436","volume":"45","author":"T Terashima","year":"2015","unstructured":"Terashima T, Yamashita T, Iida N, Yamashita T, Nakagawa H, Arai K, et al. Blood neutrophil to lymphocyte ratio as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy. Hepatol Res. 2015;45(9):949\u2013959","journal-title":"Hepatol Res"},{"issue":"1","key":"10599_CR126","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/1078-0432.CCR-18-0847","volume":"25","author":"L Goyal","year":"2019","unstructured":"Goyal L, Zheng H, Abrams TA, Miksad R, Bullock AJ, Allen JN, et al. A phase II and biomarker study of sorafenib combined with modified FOLFOX in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2019;25(1):80\u201389","journal-title":"Clin Cancer Res"},{"key":"10599_CR127","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.618206","volume":"11","author":"J Mei","year":"2021","unstructured":"Mei J, Tang YH, Wei W, Shi M, Zheng L, Li SH, et al. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus lenvatinib for advanced hepatocellular carcinoma. Front Oncol. 2021;11: 618206","journal-title":"Front Oncol"},{"issue":"1","key":"10599_CR128","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1080\/02656736.2022.2112307","volume":"39","author":"H You","year":"2022","unstructured":"You H, Liu X, Guo J, Lin Y, Zhang Y, Li C. Hepatic arterial infusion chemotherapy and sequential ablation treatment in large hepatocellular carcinoma. Int J Hyperthermia. 2022;39(1):1097\u20131105","journal-title":"Int J Hyperthermia"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10599-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-023-10599-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10599-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T04:40:41Z","timestamp":1707540041000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-023-10599-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,21]]},"references-count":128,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10599"],"URL":"https:\/\/doi.org\/10.1007\/s12072-023-10599-6","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,21]]},"assertion":[{"value":"7 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ming Zhao, Zhi Guo, Ying-Hua Zou, Xiao Li, Zhi-Ping Yan, Min-Shan Chen, Wei-Jun Fan, Hai-Liang Li, Ji-Jin Yang, Xiao-Ming Chen, Lin-Feng Xu, Yue-Wei Zhang, Kang-Shun Zhu, Jun-Hui Sun, Jia-Ping Li, Yong Jin, Hai-Peng Yu, Feng Duan, Bin Xiong, Guo-Wen Yin, Hai-Lan Lin, Yi-Long Ma, Hua-Ming Wang, Shan-Zhi Gu, Tong-Guo Si, Xiao-Dong Wang, Chang Zhao, Wen-Chang Yu, Jian-Hai Guo, Jian Zhai, Yong-Hui Huang, Wei-Yu Wang, Hai-Feng Lin, Yang-Kui Gu, Jin-Zhang Chen, Jian-Peng Wang, Yi-Min Zhang, Jun-Zhe Yi, Ning Lyu declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}